OPITECHNCT07917546
Early COMT Inhibition in PD
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Participants randomized to this arm received opicapone 50 mg orally once daily as add-on therapy to their existing levodopa/dopa-decarboxylase inhibitor (DDCI) regimen for approximately four weeks. Adjustments to levodopa dosage and administration schedule were permitted during the first two weeks based on clinical response and tolerability. Treatment efficacy was evaluated through standardized clinical assessments and seven-day home-based wearable sensor monitoring at baseline and follow-up.
Participants randomized to this arm received an additional 100-200 mg/day of levodopa combined with a dopa-decarboxylase inhibitor (DDCI) for approximately four weeks. The additional levodopa dose was administered either as an extra daily dose or distributed across existing administrations, according to the patient's treatment schedule and clinical needs. Treatment efficacy was evaluated through standardized clinical assessments and seven-day home-based wearable sensor monitoring at baseline and follow-up.
Drugs: Opicapone 50 mg, L-DOPA/DDCI
Sites
1 site in 1 country
- Sapienza University of RomeRoma, Italy, Italy